Publications by authors named "J G Ruiz-Sanchez"
: Mild autonomous cortisol secretion (MACS) can coexist with primary aldosteronism (PA). The purpose of our study was to evaluate whether (MACS) influences parameters analyzed during adrenal venous sampling (AVS) in patients with PA. : Patients with PA from the SPAIN-ALDO Registry and the German Conn's Registry with available 1 mg-dexamethasone suppression test (DST) and AVS were included.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the impact of smoking on the health profile and surgical outcomes of patients with primary aldosteronism (PA).
- In a retrospective analysis of 881 PA patients from 36 Spanish hospitals, smokers exhibited higher rates of left ventricular hypertrophy (LVH) and larger adrenal tumors compared to non-smokers, although their blood pressure and potassium levels were similar at diagnosis.
- The results indicated that while smoking is linked to a greater prevalence of LVH and mild autonomous cortisol secretion (MACS), it does not significantly influence hypertension cure rates after surgery for PA.
REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
J Diabetes Complications
December 2024
Objective: To evaluate the efficacy of switching to once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) who were previously treated with other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in a real-world setting in Spain.
Methods: The REAL Life study of SEMaglutide in Patients with Type 2 diabetes in Spain (REALSEM-SP) was conducted in four endocrinology departments in Madrid, Spain. Adult patients with T2DM who were prescribed once-weekly (OW) subcutaneous semaglutide and had been previously treated with other GLP-1 RAs were included.
Introduction: Primary aldosteronism is the most frequent cause of hypertension although is undetected. The 2016 Endocrine Society guidelines (2016-ESG) recommendations for primary aldosteronism detection are unfulfilled. We aimed to ascertain the prevalence of primary aldosteronism, following the screening criteria endorsed by the 2016-ESG.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze genetic testing rates for familial hyperaldosteronism (FH) in patients with primary aldosteronism (PA) within the SPAIN-ALDO Registry and to describe the clinical aspects of these patients.
- Out of 855 patients with PA, only 25 (3%) underwent genetic testing for FH, with complete results for just 24, highlighting a significant gap in testing as only 14% met appropriate criteria for genetic evaluation.
- The findings indicate that FH is rare, accounting for only 0.2% of PA cases in the registry, though it might be more prevalent (up to 4%) in patients suspected of having the condition, illustrating the need for increased genetic assessment in